A confirmatory study of APTA-2217 in patients with chronic obstructive pulmonary disease (A placebo-controlled double-blind, parallel group study)
Not Applicable
- Conditions
- Chronic obstructive pulmonary disease
- Registration Number
- JPRN-jRCT2080220095
- Lead Sponsor
- Mitsubishi Tanabe Pharma was the original trial sponsor; however Astra Zeneca is now the Responsible Party
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
[Inclusion criteria]
Patients with chronic obstructive pulmonary disease who are 40 years old or more, current smoker or ex-smoker, 30 to 80 % of predicted FEV1 after inhalation of short acting beta stimulant.
[Exclusion criteria]
Patients with poorly controlled COPD, patients who need for long-term oxygen therapy, patients who have concurrent respiratory diseases such as asthma, diffuse panbronchiolitis, congenital sinobronchial syndrome, bronchiolitis obliterans, bronchiectasis, active tuberculosis, pneumoconiosis, pulmonary lymph vascular myaoma), which are considered to affect the evaluation.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method